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Human adenovirus (HAdV) infection after hematopoietic stem cell transplantation (HSCT) is associated with
signiﬁcant morbidity and mortality in children. The optimal surveillance and treatment strategies are under
discussion. Here, we present data from 238 consecutive pediatric allogeneic HSCT recipients who underwent
transplantation in a single center who were included in a prospective, weekly HAdV DNAemia monitoring
program by quantitative PCR. HAdV loads >1000 copies/mL were detected in 15.5% of all patients. Despite a
low mortality directly attributed to HAdV infection (2 patients, 0.84%), blood HAdV loads >10,000 copies/mL
(6.7% of all patients) were signiﬁcant and independent risk factors for poor survival. We searched for patient,
virus, and treatment-related risk factors of HAdV DNAemia and disease. Detection of HAdV in blood before
day 50 post transplantation was a major independent risk factor for the development of blood HAdV loads
>10,000 copies/mL. HAdV typing revealed A31, C1, and C2 as the predominant pathogens among several
other HAdV strains with type C species detected in most patients with severe HAdV disease. Stool HAdV loads
were prospectively monitored in 111 patients and correlated with but did not signiﬁcantly precede detection
in blood. Treatment with cidofovir led to stable or reduced viral load in 70% of patients with blood HAdV loads
>1000 copies/mL. Thus, early occurrence of HAdV-DNA in blood of pediatric HSCT recipients predisposes for
development of high viral loads. Control of HAdV infections was attempted by preemptive cidofovir treat-
ment of patients with high blood HAdV loads or with symptomatic organ infections and correlated with low
HAdV-attributed mortality.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Human adenovirus (HAdV) infections are serious com-
plications of pediatric allogeneic hematopoietic stem cell
transplantation (HSCT) with up to 5% of pediatric HSCT pa-
tients succumbing to these infections [1e3]. Severe, dis-
seminated HAdV infections are lethal in up to 100% [4]. Risk
factors for HAdV infection are controversial but include
donor type [1], conditioning regimen [5], and T cell depletion
[6e9]. Monitoring for HAdV is recommended for pediatric
patients after HSCT [7] and quantitative HAdV polymerase
chain reaction (PCR) from peripheral blood, stool, and other
material is considered reliable, sensitive, and expeditious [2].
The incidence of HAdV detection by PCR in peripheral blood
of pediatric HSCT patients varies between 8% and 21%
[4,10e12] and high blood HAdV loads are a risk factor for
disseminated HAdV disease [13]. Although several HAdV
outbreaks have been reported in pediatric HSCT units [14,15],
HAdV infections during HSCT-related immunosuppressionedgments on page 255.
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13.11.009are mainly reactivations from asymptomatic HAdV persis-
tence in the upper respiratory tract [16], intestine [4], and/or
urinary tract [17].
Treatment options for HAdV infections are currently not
satisfying. Cidofovir is state-of-the-art for both preemptive
and therapeutic treatment of HAdV infections [7,11,18],
despite relevant toxicities [11,19]. Even with antiviral treat-
ment, clearance of HAdV is closely related to immune
reconstitution after HSCT [20]; therefore, withdrawal of
immunosuppression is advocated where possible [8]. The
use of HAdV-speciﬁc donor-derived T cells offers an addi-
tional therapeutic approach [21]. Instead of ex vivo ampliﬁed
HAdV-speciﬁc T cells, unmanipulated donor lymphocyte in-
fusions have been used with acceptable side effects, even in
haploidentical transplantations [22].
Identiﬁcation of patients at high risk for severe HAdV
disease is crucial to stratify patients to pre-emptive treat-
ment. To date, risk factor analysis is hampered by the difﬁ-
culty in comparing results of monitoring methods (mostly
PCR-based) between different transplantation centers and
laboratories. Therefore, large, single-center studies are
currently the most feasible way to approach this problem.
Here, we evaluate results of prospective quantitative
HAdV-PCR monitoring, HAdV disease, and treatment out-
come in 238 consecutive pediatric HSCT recipients whoTransplantation.
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period. We show that the magnitude of peak HAdV blood
loads correlates with overall transplantation outcome.
Therefore, we aim to identify the characteristics of patients
who will most likely beneﬁt from antiviral treatment. We
identify risk factors for the development of high peak HAdV
blood loads, and evaluate the course of antiviral treatment
with cidofovir.
PATIENTS, MATERIALS, AND METHODS
Study Concept and Data Source
This retrospective analysis was approved by the institutional review
board of Hannover Medical School. All consecutive patients undergoing ﬁrst
HSCT between January 1, 2003, and February 28, 2012, at our center were
included. Data on HAdV infection of 6 patients were previously reported
[15]. Quantitative HAdV PCR results were collected prospectively. Real-time
PCR assays and HAdV typing were performed by the German National
Reference Laboratory for Adenoviruses, Hannover Medical School. Clinical
data was retrieved from the pediatric HSCT database and medical records.
Patient Characteristics
A total of 238 consecutive pediatric allogeneic HSCT patients were
included. Median follow-up was 24 months (range, 1 to 105) for the sur-
viving patients. Patient characteristics are displayed in Table 1. Patients
underwent transplantation for both malignant (n ¼ 130) and nonmalignantTable 1
Patient Characteristics and Peak Blood HAdV Load
Characteristic n % Peak Blood HAdV
Negative Les
100
Sex
Male 138 58% 75 43
Female 100 42% 43 40
Age
<6 yr 90 38% 36 34
6 yr 148 62% 82 49
Underlying disease
Acute leukemia 98 41% 40 34
Chronic leukemia 9 4% 4 3
Solid tumors 3 1% 2 1
Lymphoma 6 3% 4 1
MDS 14 6% 11 5
SAA 13 5% 7 6
Hemoglobinopathies 23 10% 14 6
Inborn errors of hematopoiesis 23 10% 14 8
Inborn errors of metabolism 12 5% 8 2
Immunodeﬁciency syndrome/HLH 37 16% 14 17
Conditioning regimen
Treosulfan-based 73 31% 37 22
Busulfan-based 65 27% 31 22
TBI-based 65 27% 30 26
Other 35 15% 20 13
T cell depletion
No T cell depletion 36 15% 19 14
ATG/ALG 125 53% 66 40
alemtuzumab 39 16% 16 16
OKT3 4 2% 1 2
In vitro T cell depletion 34 14% 16 11
Stem cell source
MRD 77 32% 41 27
MUD 136 57% 65 47
Alternative donor 25 11% 12 9
Acute GvHD
No aGvHD 124 52% 66 43
aGvHD I 47 20% 24 15
aGvHD  II 67 28% 28 25
Chronic GvHD
No 214 90% 109 70
Yes 24 10% 9 13
ATG/ALT indicates Anti-thymocyte globulin or anti-lymphocyte globulin; HAdVs,
MDS, myelodysplastic syndrome; MRD, matched related donor; MUD, matched un
P values indicate results of Pearson’s chi-square test.disease (n ¼ 108). The majority (89%) underwent transplantation from
matched donors, whereas 25 patients received alternative stem cell grafts
(18 mismatched related donor grafts, 3 mismatched unrelated donor grafts,
and 4 cord blood grafts). Fifteen patients (6.3%) received a second HSCT.Deﬁnitions
The cause of death was deﬁned following the algorithm developed by
Copelan and colleagues [23]. A death that was classiﬁed as caused by
infection and that occurred after detection of any HAdV in a vital organ
(lung, liver, cerebrospinal ﬂuid) or blood (load >1000 copies/mL) within the
last 30 days before death was classiﬁed as HAdV-related. HAdV disease was
deﬁned as symptomatic disease with concomitant detection of HAdV at the
site of infection or in blood.HAdV Monitoring
Routine quantitative HAdV-PCR monitoring from peripheral blood was
performed weekly from the time of admission until discharge and monthly
thereafter until day þ180. A median of 18 (range, 1 to 66) samples per pa-
tient have been evaluated. After July 2008, routine quantitative HAdV-PCR
monitoring from stool was performed once weekly until discharge, and
thereafter whenever clinically indicated. A median of 5 samples (range, 0 to
41) per patient were tested. Before July 2008, stool HAdV-PCR was per-
formed only upon clinical indication.
Quantitative real-timeHAdV-PCR andmolecular typing were performed
as previously described [24e26]. Contaminationwasmonitored by adequate
negative controls. The lower quantiﬁcation limit of the quantitative PCRLoad P Value
s than
0 Copies/mL
1000 to
10,000 Copies/mL
More than
10,000 Copies/mL
.377
11 9
10 7
.065
11 9
10 7
.564
8 10
2
1
1
3
3 1
1 1
2 4
.413
6 8
9 3
4 5
2
.641
3
10 9
3 4
1
5 2
.458
8 1
11 13
2 2
.248
7 8
7 1
7 7
.143
19 16
2
human adenovirus; GvHD, graft-versus-host disease; aGvHD, acute GvHD;
related donor; SAA, severe acute anemia; TBI, total body irradiation.
Figure 1. Overall survival after pediatric hematopoietic stemcell transplantation
stratiﬁed by peak blood HAdV load.
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as positive but not quantiﬁable.
Treatment of HAdV Infection
Antiviral treatment of HAdV was considered pre-emptively if asymp-
tomatic patients had (1) more than 10,000 copies/mL in blood or (2) rising
blood copy numbers above >1000 copies/mL on at least 2 occasions, or
therapeutically in symptomatic local or systemic infection. Cidofovir was the
drug most frequently prescribed (5 mg/kg body weight intravenously once
weekly for 2 weeks, thereafter 5 mg/kg every 2 weeks). In some cases
ribavirin or HAdV-speciﬁc donor T cells were employed.
Statistics
Categorical variables were summarized using absolute frequencies.
Group comparisons were performedwith chi-square test or Fisher exact test
where appropriate. Time to death after HSCT was analyzed via Kaplan-
Meyer curves and log-rank test. Univariate Cox proportional-hazard
models were used to investigate the effect of each covariate on survival.
Proportional hazards assumption was assessed for each covariate graphi-
cally and with a goodness of ﬁt test using Schoenfeld residuals. If the
assumption was violated, an extended Cox model with Heaviside functions
was used. For themultivariate Coxmodel, all covariates with a P value< .2 in
the univariate Cox regression were assessed, and backward selection
method was applied. Furthermore, univariate logistic regressions were
performed to identify risk factors for the dependent variables peak blood
HAdV loads >1000 copies/mL and >10,000 copies/mL, respectively. Equal
decision rules as described for the multivariate Cox regression were applied
to multivariate logistic regression.
All tests were explorative; alpha was not adjusted for multiple testing.
P values  .05 were considered signiﬁcant. Calculations were performed
using statistical software programs SPSS 19.0 and SAS 9.3.
RESULTS
HAdV DNA Detection and Survival after HSCT
HAdV DNAemia was detected by routine screening in 120
of 238 patients (50.4%). Peak blood HAdV loads were below
1000 copies/mL in 83 patients (35%), and 21 patients (8.8%)
had peak blood HAdV loads between 1000 and 10,000
copies/mL (range, 1200 to 10,000 copies/mL; median 4400
copies/mL). Another 16 patients (6.7%) had peak blood HAdV
loads>10,000 copies/mL (range, 1.5104 copies/mL to 4.0
109; median, 4.5  105 copies/mL). Detection of HAdV in
blood < 1000 copies/mL was a single event in most patients.
Patients with peak blood loads of 1000 to 10,000 copies/mL
had amedian of 4 (range,1 to 21) positive samples, whereas a
median of 7.5 positive samples were detected in patients
with peak blood loads > 10,000 copies/mL.
We identiﬁed 27 of 238 (11.3%) patients with HAdV-
related symptoms (Supplemental Table S1). Twenty-four
(89%) had HAdV-associated enteropathy, 4 patients (15%)
suffered from HAdV-mediated acute respiratory distress
syndrome and/or sepsis, and 5 patients (19%) displayed signs
of disseminated HAdV disease (ie, fever, hepatitis, nephritis).
All but 1 symptomatic infection occurred before day þ100
after last HSCT, and all but 1 patient had received T cell
depletion.
At time of databank closure, 199 of 238 patients (83.6%)
were alive. Among the 39 deaths, 2 were directly attributed
to HAdV infection (Supplemental Table S1). Both patients
had HAdV disseminated disease, 1 with HAdV pneumonia
(death on day þ71) and 1 with HAdV pneumonia and hep-
atitis (death on day þ80), accounting for .84% of all patients.
Another patient died of cytomegalovirus infection with
concomitant detection of low level HAdV-DNAemia. All other
deaths, including the patients with prior HAdV disease, were
attributed to relapse (n ¼ 16), nonengraftment (n ¼ 2), graft-
versus-host disease (n ¼ 4), infections other than HAdV
(n ¼ 12), and multiorgan failure (n ¼ 3).
Impaired overall survival was associated with high peak
blood HAdV loads (Figure 1). In patients with peak bloodHAdV loads >10,000 copies/mL (hazard ratio [HR], 3.81;
P ¼ .003) this reached signiﬁcance, whereas in patients with
peak blood loads between 1000 and 10,000 copies/mL, sig-
niﬁcance was missed (HR, 1.63; P ¼ .306). Patients with peak
blood HAdV loads <1000 copies/mL had an overall survival
similar to HAdV-negative patients.
To verify whether peak blood HAdV viral loads were an
independent risk factor for death after HSCT, we performed
Cox regression analysis of potential risk factors from time of
ﬁrst HSCT to death for any reason. Only peak blood HAdV
load >10,000 copies/mL (HR, 3.05; P ¼ .019), transplantation
from an alternative donor (HR, 11.82; P < .001) and mild
acute graft-versus-host disease (HR, .29; P ¼ .046) were
signiﬁcant predictors for survival after HSCT in a multivariate
model. Transplantation from a matched unrelated donor
(MUD) tended to predispose for death (HR, 2.68; P ¼ .054)
(Tables 2a, 2b).
Risk Factors for HAdV-DNAemia
To identify patients at risk for HAdV-DNAemia, we
analyzed potential risk factors using univariate and multi-
variate logistic regression analysis (Supplementary Table S2).
In univariate analysis, detection of HAdV before day þ50
(Odds Ratio [OR], 3.04; P ¼ .012) and age at HSCT less than
6 years (OR, .45; P ¼ .029) were signiﬁcantly associated with
blood HAdV levels >1000 copies/mL. Univariate risk factors
for blood HAdV loads >10,000 copies/mL were detection of
HAdV before day þ50 (OR, 6.00; P ¼ .022) and trans-
plantation from matched unrelated donor (OR, 7.93; P ¼
.048). In multivariate analysis, only detection of virus before
day þ50 remained a signiﬁcant risk factor for both blood
HAdV loads >1000 copies/mL (OR, 3.04; P ¼ .012) and
>10,000 copies/mL (OR, 6.00; P ¼ .022), respectively.
HAdV Monitoring of Stool Samples
Prospective PCR-based monitoring of HAdV in stool
samples was established in July 2008. We evaluated whether
stool monitoring was helpful to predict HAdV-DNAemia,
which may provide early treatment options. Forty-eight of
Table 2b
Multivariate Cox Regression for Survival after First HSCT
Characteristic n % HR CI 95% P Value
Stem cell donor
MRD 77 32% 1.00 reference
MUD 136 57% 2.68 .98-7.28 .054
alternative donor 25 11% 11.82 4.14-33.72 <.001
aGvHD
no aGvHD 124 52% 1.00 reference
aGvHD I 47 20% .29 .09-.98 .046
aGvHD  II(< 18 mo) 33 14% .66 .30-1.46 .307
aGvHD  II( 18 mo) 34 14% 3.60 .76-17.11 .107
Peak blood HAdV load
negative 118 50% 1.00 reference
<1000 copies/mL 83 35% .58 .26-1.30 .183
1000-10,000 copies/mL 21 9% 1.69 .65-4.40 .280
>10,000 copies/mL 16 7% 3.05 1.20-7.77 .019
HSCT indicates hematopoietic stem cell transplantation; HR, hazard ratio; CI,
conﬁdence interval; HAdV, human adenovirus; aGvHD, acute graft-versus-
host disease; MRD, matched related donor; MUD, matched unrelated donor.
The Cox model was extended with a Heaviside function for aGvHD since the
proportional hazard assumption was not fulﬁlled in this variable.
Table 2a
Univariate Cox Regression for Survival after First HSCT
Characteristic n % HR CI 95% P Value
Sex
Male 138 58% 1.00 reference
Female 100 42% 1.04 .55-1.96 .903
Age at transplantation
6 yr 90 38% 1.00 reference
>6 yr 148 62% .73 .39-1.37 .331
Malignant disease
No 108 45% 1.00 reference
Yes 130 55% 1.790 .92-3.49 .086
Conditioning regimen
Treosulfan-based 73 31% 1.00 reference
Busulfan-based 65 27% .70 .33-1.49 .353
TBI-based 65 27% .65 .29-1.46 .298
Other 35 15% .23 .05-.99 .048
T cell depletion
No T cell depletion 36 15% 1.00 reference
ALG/ATG 125 53% 1.13 .42-3.03 .809
Alemtuzumab 39 16% .38 .07-1.94 .241
Okt3 4 2% 2.21 .26-18.97 .469
In vitro T cell depletion 34 14% 2.46 .87-6.99 .091
Stem cell donor
MRD 77 32% 1.00 reference
MUD 136 57% 2.77 1.05-7.36 .041
Alternative donor 25 11% 11.50 4.09-32.64 <.001
aGvHD
No aGvHD 124 52% 1.00 reference
aGvHD I 47 20% .30 .09-1.00 .05
aGvHD  II(< 18 months f.u.) 33 14% .88 .41-1.89 .743
aGvHD  II( 18 months f.u.) 34 14% 3.38 .74-15.42 .115
cGvHD
No 214 90% 1.00 reference
Yes 24 10% 1.25 .49-3.21 .639
Peak blood HAdV load
Negative 118 50% 1.00 reference
<1000 copies/ml 83 35% .75 .34-1.66 .482
1000-10,000 copies/ml 21 9% 1.63 .64-4.19 .306
>10,000 copies/ml 16 7% 3.81 1.57-9.29 .003
HSCT indicates hematopoietic stem cell transplantation; HR, hazard ratio;
CI, conﬁdence interval; HAdV, human adenovirus; aGvHD, acute graft-
versus-host disease; cGvHD, chronic graft-versus-host disease; f.u., follow
up; MDS, myelodysplastic syndrome; MRD, matched related donor; MUD,
matched unrelated donor; SAA, severe acute anemia; TBI, total body
irradiation.
The Cox model was extended with a Heaviside function for aGvHD since the
proportional hazard assumption was not fulﬁlled in this variable.
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least 1 positive result after HSCT; 18 (16.2%) of these had
peak stool HAdV load >106 copies/mL. All 7 patients with
peak blood HAdV loads >10,000 copies/mL in this group had
simultaneous detection of HAdV at levels more than 106
copies/mL in stool (Fischer exact test: P < .001). In 4 of the 7
patients, increasing stool HAdV loads were detected before
increasing blood HAdV loads. In the remaining 3 patients,
HAdV loads increased simultaneously in blood and stool.
Detection of >106 HAdV copies/mL in stool preceded
appearance of blood HAdV load >1000 copies/mL by a me-
dian of 5 days (range, -22 to 34 days).
HAdV Typing
We questioned whether the magnitude of peak HAdV
load and/or of HAdV disease is restricted to certain HAdV
strains. HAdV typing was successful in 42 patients from stool
(n¼ 37), blood (n¼ 12), tissue biopsies (n¼ 2), or respiratory
samples (n ¼ 4) (Table 3). Seven HAdV types were encoun-
tered; however, HAdV-A31, -C1, and -C2 were the predomi-
nant types. Both patients who died of HAdV experienced
type C2 species infections, whereas A31 was predominantly
detected in stool and was not detected in fatal cases(Supplemental Table S1). However, HAdV genotyping was
laborious and time consuming; thus, it fails to signiﬁcantly
contribute to treatment decisions but helps to detect trans-
mission routes.Response to Cidofovir Therapy
Antiviral therapy with cidofovir was initiated in 45 pa-
tients to treat HAdV. Eighteen of 45 patients had blood
HAdV loads >1000 copies/mL at their ﬁrst dose of cidofovir.
The decrease in median blood HAdV loads during the ﬁrst 4
doses of cidofovir was paralleled by an increase in median
total lymphocyte count (Figure 2). Fourteen patients cleared
their virus and 4 died during cidofovir treatment (after 1, 3,
5, and 6 doses, respectively) with positive blood HAdV PCR.
Two fatal cases (patient no. 03 and no. 106) were unequiv-
ocally attributed to HAdV infection; the others died of leu-
kemia relapse (patient no. 127) and nonengraftment
(patient no. 247). Of the remaining 27 patients, 14 received
cidofovir as treatment of symptomatic HAdV organ in-
fections despite low (<1000 copies/mL) or negative HAdV
DNAemia. The remaining 13 HAdV positive patients were
treated with cidofovir after detection of low level HAdV
(<1000 copies/mL) because they were considered at high
risk of HAdV disease at the physician’s decision. In 8 of 27
patients (30%), blood HAdV loads increased transiently
despite antiviral therapy (to 1000 to 10,000 copies/mL in 3
patients and to >10,000 copies/mL in 5 patients). However,
all patients cleared HAdV from their blood and none of the
deaths (n ¼ 4) in this group were associated with HAdV
infection.
Another28patients receivedcidofovir forother indications,
mainlycytomegalovirus andBK-virus (BKV)-infections.During
treatment with cidofovir, 11 of 28 patients (39%) developed
HAdV DNAemia. Infections were asymptomatic in most cases,
with peak blood HAdV loads < 1000 copies/mL in 9 patients.
Patients no. 38 and no. 165 developed HAdV-related diarrhea
and had peak bloodHAdV loads of 5600 copies/mL and 10,000
copies/mL, respectively. Both died with active HAdV infection
from relapse (patient no. 165) and CMV infection (patient
no. 138).
During cidofovir treatment, creatinine levels did not in-
crease signiﬁcantly (data not shown); 7 of 73 patients treated
with cidofovir required dose adjustment.
Table 3
HAdV Genotyping
Genotype n % Patients According to Peak Blood HAdV Loads Patients with
Positive Stool PCR
Less than 1000 Copies/mL 1000 to 10,000 Copies/mL More than 10,000 Copies/mL
A18 1 2% 0 1 0 1
A31 10 22% 4 4 2 10
B3 3 7% 1 0 1 2
C* 2 4% 0 0 1 2
C1 8 17% 1 2 4 8
C2 17 37% 7 2 5 15
C6 1 2% 0 1 0 1
F41 4 9% 0 1 3 4
Number of patients with successful HAdV genotyping. Patients are further divided according to peak blood HAdV loads. Patients with a history of positive stool-
PCR results are displayed separately.
* HAdV of species C but precise typing failed.
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HAdV-speciﬁc donor Tcells were administered in patients
no. 103, no. 120, and no. 370. In 2 patients, HAdV infection
resolved. Patient no. 103 was in very poor clinical conditions
at time of cell therapy and died of systemic HAdV infection
2 days after T cell transfer.
DISCUSSION
This study evaluates the results of a routine monitoring
program for HAdV DNAemia in 238 pediatric allogeneic HSCT
recipients, aiming at identiﬁcation of decision routes for early
riskeadapted antiviral treatment. Althoughmortality directly
attributed to HAdV in our cohort was relatively low (.8%)
compared with other published results [1,4,10e12,14,27,28],
peak HAdV blood levels of >10,000 copies/mL were an inde-
pendent risk factor of poor overall survival. This is in accor-
dance with results of a previous study [29] and may be
interpreted as a surrogate of poor immune reconstitution
leading to both susceptibility to infection and high probability
of disease relapse.
Patients with HAdV-DNAemia detected before day þ50
post HSCT were at high risk of developing peak HAdV levels
>10,000 copies/mL. Antiviral immunity is most impairedFigure 2. Blood HAdV load and total lymphocyte count (TLC) of 17 patients
during cidofovir treatment. White bars reﬂect TLC, grey bars blood HAdV load,
both presented as box plots. Black lines indicate median values, boxes indicate
25% and 75% quantiles and whiskers, minimum and maximum values. HAdV
virus loads below the threshold of quantiﬁcation (1000 copies/mL) were
depicted as 1000 copies/mL, negative values as 1 copy/mL.shortly after transplantation and, therefore, HAdV reac-
tivation is less likely to be controlled. In contrast to previous
studies [8,9,21], we could not attribute a signiﬁcant adverse
effect to Tcell depletion in general. However, high peak blood
HAdV loads >10,000 copies/mL were restricted to patients
who received T cell depletion. Other risk factors, such as
donor type [1] or conditioning regimen [5], missed prog-
nostic signiﬁcance.
In addition to exploring host factors, we asked whether
HAdV genotyping may support risk estimation in infected
patients. Typing revealed a wide range of HAdV species,
which did not shift over the 9-year monitoring period.
Although the type of the virus did not correlate with severity
of infection (data not shown), both patients who succumbed
directly to HAdV suffered from HAdV-C2 infections. In
contrast, HAdV-A31 was a frequent, but not life-threatening
infection. Because genotyping is laborious and time
consuming, it had limited impact on therapeutic decisions
but it helped to detect transmission routes. The wide
multitude of types and the predominance of species HAdV-C
(Table 3), which is capable to persist in immunocompetent
individuals [16,30], suggested that, with the exception of the
HAdV-F41 outbreak published 2008 [15], most infections
were reactivations of persisting virus. Once acquired, HAdV
may persist in lymphorecticular tissue and viral shedding
can occur for months to years. The high incidence of HAdV
infection in patients younger than 6 years in this study is
consistent with the high prevalence of acute (and usually
mild) HAdV infections in otherwise healthy toddlers [31,32]
and the resulting high prevalence of asymptomatic HAdV
persistence in this age group [16,30].
There was no signiﬁcant change in peak viral load over
the monitoring period of 9 years (data not shown). The high
incidence of HAdV-DNAemia (50.4%) compared with inci-
dence shown in previous studies (8% to 38%) [4,10e12,33]
may be explained by the use of whole blood as PCR
template, together with a highly sensitive quantitative
PCR-assay. HAdV DNA persisting in blood lymphocytes
(“latency”) [16] may occasionally lead to low positive results,
even without active virus replication. This is in line with the
ﬁnding that detection of HAdV in blood below the level of
quantiﬁcation was a single event in most patients. Fifteen
percent of patients had harbored HAdV-DNAemia >1000
copies/mL, which is in line with a recently published study
by Lee et al. [9]. Only 11.3% (27 of 238) of the patients had
HAdV-related symptoms, thus indicating a signiﬁcant rate of
subclinical infections.
Monitoring of HAdV in stool was initiated in 2008 after an
HAdV-F41 outbreak on the pediatric HSCT unit [15]. The
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only marginally preceded, detection of HAdV in peripheral
blood. Peak stool viral loads >106 copies/mL were associated
with peak blood HAdV loads >10,000 copies/mL. This is
consistent with a previous study by Lion et al. [4], although
the median interval between detection of HAdV in stool and
HAdV-DNAemia was shorter (5 versus 11 days). Therefore,
stool testing only marginally improved early recognition of
patients at risk for high-load HAdV-DNAemia. It may have
facilitated control of nosocomial spread, as transmission and
hygiene precautions were instituted for positive stool HAdV.
Compared with results from other studies
[1,4,10e12,14,27,28], the HAdV-related post-HSCT mortality
in our cohort was strikingly low at .8%, despite a high inci-
dence of HAdV-DNAemia. This is unexpected and difﬁcult to
interpret, even considering differing deﬁnitions of HAdV-
related death between studies. It may be speculated that
this lowmortality was due to diligent pre-emptive treatment
for at risk patients. Upon treatment with cidofovir, HAdV
levels in blood decreased in the majority of patients, sup-
porting the hypothesis that the drug helped to control
infection. However, this study was not designed to evaluate
the efﬁcacy of cidofovir. Therefore, results on cidofovir ther-
apymust be interpreted cautiously. For example, clearance of
HAdVwas paralleled by reconstitution of the lymphocyte cell
compartment and, presumably, HAdV-speciﬁc cellular im-
munity [21] and, thus, cannot be associated unequivocally
with the application of cidofovir. Moreover, HAdV loads
increased during cidofovir therapy in somepatients, and 11 of
28 patients treated with cidofovir for other indications
developed HAdV DNAemia during treatment.
Despite the low HAdV-related mortality in this study,
HAdV infection accounted for 5.1% of all deaths in our cohort.
This serious complication affected many individuals, and
better treatment modalities are urgently warranted. The
controlled phase II clinical trial on pre-emptive HAdV ther-
apy with CMX001, a lipid conjugate of cidofovir (Clinical
Trials.gov ID: NCT01241344) has been completed recently,
but results are pending. HAdV-speciﬁc T lymphocytes are
another promising option for both prevention and therapy of
adenoviral infection in HSCT patients. Trials heading towards
the better understanding of adenoviral immunity and ﬁrst
clinical trials evaluating the efﬁcacy of HAdV-speciﬁc T cells
are currently ongoing.
As a result of our data, we recommendweekly HAdV blood
monitoring for at least 50 days for pediatric HSCT recipients.
Reduction of immunosuppressive therapy (if feasible) and
pre-emptive treatment with cidofovir should be started in
patients at risk (HAdVDNAemia>10,000 copies/mL in a single
sample, DNAemia >1000 copies/mL in at least 2 samples or
increasing virus loads). Moreover, we recommend treating
HAdV organ infections (eg, cystitis, enteritis, pneumonia) as
early as possible and independently of results of HAdV
DNAemia monitoring. Adoptive T cell therapy should be
considered in patients not responding to cidofovir treatment.ACKNOWLEDGMENTS
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